These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22234528)

  • 1. Mutations in epigenetic regulators in myelodysplastic syndromes.
    Nikoloski G; van der Reijden BA; Jansen JH
    Int J Hematol; 2012 Jan; 95(1):8-16. PubMed ID: 22234528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Epigenetic Modifications in Myeloid Malignancies.
    Venney D; Mohd-Sarip A; Mills KI
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid malignancies: mutations, models and management.
    Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
    BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of mutations in epigenetic regulators in myeloid malignancies.
    Shih AH; Abdel-Wahab O; Patel JP; Levine RL
    Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
    Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
    J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics in myelodysplastic syndromes.
    Heuser M; Yun H; Thol F
    Semin Cancer Biol; 2018 Aug; 51():170-179. PubMed ID: 28778402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics factors associated with myelodysplastic syndromes.
    Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC; Agosto-Peña J
    Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of myelodysplastic syndromes: new insights.
    Graubert T; Walter MJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
    Zhang SJ; Abdel-Wahab O
    Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
    Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
    J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms.
    Dumas PY; Mansier O; Prouzet-Mauleon V; Koya J; Villacreces A; Brunet de la Grange P; Luque Paz D; Bidet A; Pasquet JM; Praloran V; Salin F; Kurokawa M; Mahon FX; Cardinaud B; Lippert E
    BMC Cancer; 2018 Nov; 18(1):1098. PubMed ID: 30419846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.